Abstracts

466 – Mapping the Spatial Landscape of Lymph Nodes With Undetectable Versus Active HIV Replication

Background Despite its effectiveness in suppressing active HIV replication, antiretroviral therapy (ART) does not eliminate the long-lived pool of HIV reservoir cells. Lymphoid tissues are a major reservoir even in the context of ART, but most studies on latent reservoirs focus on peripheral blood. The complex interplay between immune cells and the mechanisms that maintain…

559 – Paucity of HIV Envelope Expressing Cells Upon Latency Reversal in ART-Suppressed PWH

Background Antiretroviral therapy (ART) effectively suppresses HIV-1 replication but fails to eradicate the virus, as HIV-1 persists in long-lived reservoirs. Therefore, novel strategies are needed to detect and eliminate them. The HIV-1 envelope glycoprotein (Env) is the only viral antigen expressed on the surface of infected cells, making it a prime target for immunotherapies. While current…

538 – Phase I Clinical Trial AMC097 Evaluating Engraftment and HIV Resistance of Gene-Modified Blood Cells

Background For HIV patients, there is currently no effective cure.  Approaches involving stem cell and gene therapies aimed at mimicking the results of the Berlin Patient and others have been developed including ongoing human clinical trials.  There is an urgent need for strategies that expand gene therapy beyond CCR5 modification to target multiple stages of HIV…

417 – Public Trimer-Specific IgHV4-34 Clonotype in bNAb Inducers Includes a Novel V3-Glycan bNAb Subclass

Background Several classes of HIV-1 broadly neutralizing antibodies (bnAbs) exhibit distinct immunoglobulin heavy chain variable (IGHV) gene usage, and many HIV vaccine strategies aim to elicit public bnAb clonotypes. Here, we performed a systematic analysis of HIV-1 envelope (Env) trimer reactive B cell receptor (BCR) repertoires in bnAb inducers to define public features of IGHV…

339 – Sustained Inflammation and Delayed Resolution of COVID-19 Disease in SIV-Infected Macaques

Background COVID-19 continues to be a health challenge with critical knowledge gaps existing in the understanding of mechanisms driving severity in comorbid conditions. Clinical observations points to a higher susceptibility to COVID-19 in people living with HIV (PLHIV) but the precise mechanisms are still unknown. Methods Our group was amongst few that established the rhesus…

506 – Sustained T Cell-Mediated Immunity After LS-bNAbs in the RIO Trial: A Vaccinal Effect

Background T cell immunity may explain sustained viral control off ART after bNAbs in non-human primates, but evidence from human trials is limited. Proof of a bNAb-induced ‘vaccinal effect’ requires evidence of both enhanced HIV-specific immunity and associated viral control. The RIO trial facilitated analysis of participants receiving two LS-bNAbs (10-1074 & 3BNC117) followed by…

459 – Tri-Specific Killer Engagers in Macaques Potently Induce NK Cell Responses in Blood and Tissues

Background Strategies to enhance immune responses towards HIV-infected cells are needed for eliminating HIV reservoirs. Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) plays a key role in HIV protection. In cancer, Tri-specific Killer Engagers (TriKEs), consisting of a CD16-binding domain, an antigen-targeting domain, and an IL-15 moiety, enhance NK cell-mediated ADCC by forming immune synapses…

332 – Unique SARS-CoV-2 Variants and Inflammatory Milieu in Urine of Severe COVID-19 Participants

Background Acute kidney injury (AKI) is a common complication in people hospitalized with COVID-19. The etiology of AKI is likely multifactorial, with potential contributions from hemodynamic compromise, systemic inflammation, cytokine release, and local viral infection. People with COVID-19 and AKI have higher levels of systemic markers of inflammation than those with normal kidney function. To…

415 – Antigen Affinity Ceiling for Selection of Functional Mutations and HIV-1 Neutralization

Background The mechanism by which B cells sense antigen affinity and initiate signaling that leads to full B activation and differentiation remains unclear. Understanding the relationship between antigen affinity/kinetic rates and selection of functional mutations is critical for HIV-1 Envelope (Env) protein immunogens designed to target broadly neutralizing antibody (bnAb) precursors. Previously, we had reported…